Key Takeaways
- AVITA Medical’s Cohealyx-I study shows a mean time to skin grafting of 13.6 days, significantly faster than the benchmark of 33.2 days.
- The company’s FY2025 report indicates an 11% revenue increase to USD 71.6 million, but a reduction in gross margin and a net loss of USD 48.6 million.
- A new SEC shelf registration allows for potential future offerings of up to USD 200 million, enhancing financial flexibility.
Study Results and Implications
AVITA Medical (ASX: AVH) has reported promising interim results from its Cohealyx-I study, highlighting a notable reduction in the time required for skin grafting. In this multi-centre, post-market study involving 40 patients, the average grafting time was recorded at just 13.6 days, a significant improvement compared to the historical benchmark of 33.2 days. The study also reported a median grafting time of 11 days, with some patients achieving grafting as early as 5 days; 25% were grafted within 7 days, and 72% within 14 days. High levels of clinician satisfaction were noted, with 90% of participating clinicians, many of whom were first-time users, expressing positive feedback.
Financial Performance Highlights
In addition to the clinical findings, AVITA released its annual report for FY2025, which showed an 11% increase in revenue to USD 71.6 million. However, the gross margin fell to 82.1%, down from 85.8% the previous year, primarily due to a shift in product mix and increased inventory reserves. Despite these challenges, the company succeeded in reducing its net loss attributable to owners by 21%, bringing it down to USD 48.6 million, aided by lower operating expenses. As of December 31, 2025, AVITA had cash and marketable securities totaling USD 18.1 million.
Future Financial Strategy
To bolster its financial position, AVITA established a senior secured credit facility of up to USD 60 million in January 2026. Additionally, on March 31, 2026, the company filed a new SEC Form S-3 shelf registration statement, enabling the potential future offering of up to USD 200 million in various securities. While AVITA has not indicated immediate plans to utilize this option, it maintains the flexibility for future capital needs depending on market conditions.
Market Outlook and Investor Cautions
The encouraging results from the Cohealyx-I study could enhance the product’s market proposition and pave the way for broader clinical adoption. However, investors remain cautious as AVITA navigates ongoing financial hurdles, including recurring losses and the importance of managing liquidity. Key concerns include compliance with debt obligations, the risk of future equity dilution from capital raising efforts, and uncertainties regarding reimbursement for new indications.
The content above is a summary. For more details, see the source article.